Company: PACB
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001299130-25-000156
Chunk: 9

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 9
---
 12,828 Loss before income taxes(41,895)(173,319)(468,272)(251,497)Income tax provision (benefit)35 — (267)— Net loss(41,930)(173,319)(468,005)(251,497)Other comprehensive income:Unrealized loss on investments (114)(217)(155)(742)Comprehensive loss$(42,044)$(173,536)$(468,160)$(252,239)Net loss per share:Basic $(0.14)$(0.64)$(1.57)$(0.93)Diluted $(0.14)$(0.64)$(1.57)$(0.93)Weighted average shares outstanding used in calculating net loss per share:Basic 300,162272,385298,519270,982Diluted 300,162272,385298,519270,982

See accompanying notes to the condensed consolidated financial statements. 

Q2 Fiscal 2025 Form 10-Q4

Table of Contents

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(Unaudited)

Three Months Ended June 30, 2025Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensive IncomeAccumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at March 31, 2025300,041$300 $2,665,958 $381 $(2,575,001)$91,638 Net loss—— — — (41,930)(41,930)Other comprehensive loss—— — (114)— (114)Issuance of common stock in conjunction with equity plans309— — — — — Share-based compensation expense—— 11,895 — — 11,895 Balance at June 30, 2025300,350$300 $2,677,853 $267 $(2,616,931)$61,489 

Six Months Ended June 30, 2025Common StockAdditional Paid-inCapitalAccumulatedOtherComprehensiveIncomeAccumulated DeficitTotalStockholders'Equity(In thousands)SharesAmountBalance at December 31, 2024294,418$294 $2,654,804 $422 $(2,148,926)$506